Giant reactions to tuberculin in lepromatous leprosy patients.
Waters MF, Stanford JL. International journal of leprosy & other Mycobactial diseases. 1985; 53(4):546-53.
Human vaccination studies in normal and contacts of leprosy patients.
Samuel NM, Stanford JL, Rees RJ, Fairbairn T, Adiga RB. Indian journal of leprosy. 1984; 56(1):36-47.
Leprosy research, present and future.
Stanford JL. Acta leprologica. 1984; (95):421-5.
A further investigation of skin-test responsiveness and suppression in leprosy patients and healthy school children in Nepal.
Morton A, Nye P, Rook GA, Samuel N, Stanford JL. Leprosy review. 1984; 55(3):273-81.
Skin testing with mycobacterial reagents in leprosy.
Stanford JL. Tubercle. 1984; 65(1):63-74.
The BCG trials.
Stanford JL. The Practitioner. 1983; 227(1376):x-xiii.
HLA-DR3 associated genetic control of response to multiple skin tests with new tuberculins.
van Eden W, de Vries RR, Stanford JL, Rook GA. Clinical and experimental immunology. 1983; 52(2):287-92.
The demonstration of two types of suppressor mechanism in leprosy patients and their contacts by quadruple skin-testing with mycobacterial reagent mixtures.
Nye PM, Price JE, Revankar CR, Rook GA, Stanford JL. Leprosy review. 1983; 54(1):9-18.
Absence of antibodies to muramyl dipeptide in patients with tuberculosis or leprosy.
Bahr GM, Modabber FZ, Rook GA, Mehrotra ML, Stanford JL, Chedid L. Clinical and experimental immunology. 1982; 47(1):53-8.
The epidemiological evaluation, in Burma, of the skin test reagent LRA6; a cell-free extract from armadillo-derived Mycobacterium leprae. Part 2: Close contacts and non-contacts of bacilliferous leprosy patients.
Shield MJ, Stanford JL. International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association. 1982; 50(4):446-54.
Use Ris for EndNote, Mendeley, RefWorks, Zotero and most other reference management software.